Incannex Healthcare Plunges 32.39% Despite Positive Trial Results

On July 31, 2025, Incannex Healthcare experienced a significant drop of 32.39% in pre-market trading, marking a notable decline in its stock performance.

Incannex Healthcare Inc. recently reported positive topline results from the RePOSA Phase 2 trial of IHL-42X. The trial demonstrated compelling clinical benefits and an outstanding safety profile that exceeded expectations. This positive outcome is likely to have influenced investor sentiment, contributing to the stock's recent volatility.

Additionally, Incannex Healthcare has expanded its clinical advisory board to support its obstructive sleep apnea program. The appointment of Dr. Douglas B. Kirsch, a renowned expert in the field, is expected to enhance the company's research and development efforts, potentially driving future growth and innovation.